Business
Hims & Hers Announces Strategic Shift for US Weight Loss Business
SAN FRANCISCO, March 09, 2026--Hims & Hers Health, Inc. (NYSE: HIMS) today announced a collaboration with Novo Nordisk as part of a new strategy for weight loss care treatments involving GLP-1s, evolving its US offering to match the company’s approach globally. In the US, the company now plans to provide GLP-1 customers with access to a broad assortment of FDA-approved medications and offer compounded semaglutide through the platform on a limited scale. By aligning its domestic and international
About this update from Hims & Hers Health, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2562,"height":408,"url":"https://media.zenfs.com/en/business-wire.com/c02fdef689961fb607404d02e482f633"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lNB9.s1BQomGobm3iuLblQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE1MztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c02fdef689961fb607404d02e482f633","width":960,"height":153},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/amVc2LE7w4qEd6v6UbhKxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zODI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/c02fdef689961fb607404d02e482f633","width":1200,"height":191}},"lazy":false},{"type":"text","content":"Starting with a new collaboration with Novo Nordisk, the company announced plans to align its US and global strategies with a focus on an increasing variety of FDA-approved GLP-1s","length":179,"tagName":"p","attribs":{}},{"type":"text","content":"SAN FRANCISCO, March 09, 2026--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today announced a collaboration with Novo Nordisk as part of a new strategy for weight loss care treatments involving GLP-1s, evolving its US offering to match the company’s approach globally. In the US, the company now plans to provide GLP-1 customers with access to a broad assortment of FDA-approved medications and offer compounded semaglutide through the platform on a limited scale. By aligning its domestic and international models in weight loss, Hims & Hers will become the largest global consumer health platform for access to more affordable, approved medications.","length":669,"tagName":"p"},{"type":"text","content":"The US weight loss landscape has transformed dramatically since Hims & Hers entered the market in 2023. Progress in the industry has made a broader range of FDA-approved GLP-1 treatments available at more affordable prices, with more flexible dosing options and greater diversity of form factors, accelerating customer demand for branded, FDA-approved medications.","length":368,"tagName":"p"},{"type":"text","content":"As a part of this shift, the company will no longer advertise compounded GLP-1 offerings on its platform or in its marketing, and existing patients will have the opportunity to transition to FDA-approved medicines when determined...